CA1079637A - Cephalosporine tablets - Google Patents
Cephalosporine tabletsInfo
- Publication number
- CA1079637A CA1079637A CA262,741A CA262741A CA1079637A CA 1079637 A CA1079637 A CA 1079637A CA 262741 A CA262741 A CA 262741A CA 1079637 A CA1079637 A CA 1079637A
- Authority
- CA
- Canada
- Prior art keywords
- weight
- tablet according
- tablet
- orally active
- disintegrant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HOKIDJSKDBPKTQ-UHFFFAOYSA-N 3-(acetyloxymethyl)-7-[(5-amino-5-carboxypentanoyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C(NC(=O)CCCC(N)C(O)=O)C12 HOKIDJSKDBPKTQ-UHFFFAOYSA-N 0.000 title 1
- 229930186147 Cephalosporin Natural products 0.000 claims abstract description 13
- 229940124587 cephalosporin Drugs 0.000 claims abstract description 13
- 150000001780 cephalosporins Chemical class 0.000 claims abstract description 13
- 239000011230 binding agent Substances 0.000 claims abstract description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000007884 disintegrant Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 238000006073 displacement reaction Methods 0.000 claims description 6
- 229940057995 liquid paraffin Drugs 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 3
- 239000008109 sodium starch glycolate Substances 0.000 claims description 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 2
- 241000965481 Darksidea alpha Species 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 229940106164 cephalexin Drugs 0.000 abstract description 5
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 abstract description 5
- 229940047526 cephalexin monohydrate Drugs 0.000 description 8
- YGZIWEZFFBPCLN-UHFFFAOYSA-N n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OOC1CCOP(=O)(NCCCl)N1CCCl YGZIWEZFFBPCLN-UHFFFAOYSA-N 0.000 description 8
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 8
- 229920003110 Primojel Polymers 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 241001443715 Fusarium oxysporum f. sp. conglutinans Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960002588 cefradine Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000288113 Gallirallus australis Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB41744/75A GB1560475A (en) | 1975-10-11 | 1975-10-11 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1079637A true CA1079637A (en) | 1980-06-17 |
Family
ID=10421183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA262,741A Expired CA1079637A (en) | 1975-10-11 | 1976-10-05 | Cephalosporine tablets |
Country Status (6)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE13486T1 (de) * | 1980-11-12 | 1985-06-15 | Ciba Geigy Ag | Schnellzerfallende arzneimittel-presslinge. |
| JPS59155310A (ja) * | 1983-02-21 | 1984-09-04 | Daicel Chem Ind Ltd | 崩壊性の改良された固型薬剤の製造方法 |
| JPS59167522A (ja) * | 1983-03-14 | 1984-09-21 | Daicel Chem Ind Ltd | 固型薬剤の製造法 |
| JPS59176217A (ja) * | 1983-03-28 | 1984-10-05 | Daicel Chem Ind Ltd | 固形薬剤用粉粒体組成物 |
| JPS59193815A (ja) * | 1983-04-15 | 1984-11-02 | Daicel Chem Ind Ltd | 錠剤の製法 |
| JPS62173183A (ja) * | 1986-01-25 | 1987-07-30 | マツダ株式会社 | 組立搬送治具への物品取付け方法 |
| US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
-
1975
- 1975-10-11 GB GB41744/75A patent/GB1560475A/en not_active Expired
-
1976
- 1976-09-30 AU AU18292/76A patent/AU514174B2/en not_active Expired
- 1976-10-05 CA CA262,741A patent/CA1079637A/en not_active Expired
- 1976-10-06 DD DD195197A patent/DD126926A5/xx unknown
- 1976-10-08 JP JP51121193A patent/JPS5247914A/ja active Granted
- 1976-10-08 AT AT749476A patent/AT348670B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU1829276A (en) | 1978-04-06 |
| DD126926A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1977-08-24 |
| AU514174B2 (en) | 1981-01-29 |
| JPS5247914A (en) | 1977-04-16 |
| GB1560475A (en) | 1980-02-06 |
| ATA749476A (de) | 1978-07-15 |
| JPS619283B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1986-03-22 |
| AT348670B (de) | 1979-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4143129A (en) | Cephalexin tablets | |
| CA1338467C (en) | Pharmaceutical composition, pharmaceutical granulate and process for their preparation | |
| EP0223590B2 (en) | Substained release compositions comprising hydroxypropyl cellulose ethers | |
| KR100468204B1 (ko) | 베타-락탐화합물을함유하는응집체 | |
| US5286492A (en) | Method of treatment of Heliobacter pylori infections with triclosan | |
| HU219348B (en) | Compact, antibacterial preparations with granular structure and process for production of them | |
| CZ295893B6 (cs) | Granulát a rychle se rozvolňující a rychle rozpustná kompozice | |
| US3453360A (en) | Universally useful stock material for manufacturing plastic dosage units by compression tableting processes | |
| US3865935A (en) | Tableting of erythromycin base | |
| CA1079637A (en) | Cephalosporine tablets | |
| AU702585B2 (en) | Pharmaceutical formulations of cefaclor | |
| JP2901635B2 (ja) | アルギネートとポリアクリレートの混合物及びその使用 | |
| AU2002224011B2 (en) | A pharmaceutical composition for controlled release of a beta-lactam antibiotic | |
| JPH08310969A (ja) | 固形薬品組成物及びその製造方法 | |
| AU611740B2 (en) | Pharmaceutical composition and process for its preparation | |
| CA2280925A1 (en) | Stabilized cefuroxime axetil | |
| IE42952B1 (en) | Tablet formulation | |
| EP0519371B1 (en) | Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions | |
| US5547943A (en) | Sucralfate preparation | |
| KR960000429B1 (ko) | 니트로푸란토인의 경구투여용 서방성/속방성 약제학적 복합 캅셀 | |
| KR910004481B1 (ko) | 용출성이 개량된 제제 조성물 | |
| EP0768874A1 (en) | Pharmaceutical compositions containing Triclosan or derivates thereof and Edta or Egta | |
| CN110179990A (zh) | 一种头孢布烯组合物及其颗粒剂和该颗粒剂的制备方法 | |
| MXPA98007440A (en) | Agglomerates containing beta-lact compounds | |
| HK1012574B (en) | Pharmaceutical formulations of cefaclor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |